{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024400","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.843421+00:00","generated_at":"2026-06-13T08:55:48.830230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biofrontera Q2 2023 preliminary revenue $5.7M-$5.9M, up 26%-31% YoY; reaffirms FY growth 25%","bullets":["Q2 2023 preliminary revenue range $5.7M-$5.9M, a 26%-31% increase over Q2 2022.","H1 2023 revenue estimated at $14.4M-$14.6M, reflecting 1%-3% growth YoY.","Full-year 2023 revenue growth reaffirmed at least 25% over 2022.","Management cites increasing adoption of photodynamic therapy and larger contract wins."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024400","json":"https://secwatch.observer/filing/0001493152-23-024400.json","markdown":"https://secwatch.observer/filing/0001493152-23-024400.md","text":"https://secwatch.observer/filing/0001493152-23-024400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/0001493152-23-024400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:55:48.830230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0984fdc5c808ac4a559faa22a6a18b419cd4a11f","claim":"Biofrontera Inc. reported the six months ended June 30, 2023 results: revenue in the range of approximately $14.4 million to $14.6 million. Guidance reaffirmed.","evidence_excerpt":"of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the range of approximately $14.4 million to $14.6 million, representing growth of approximately 1% to 3% compared with the first half of 2022. “We are proud of the hard work of our commercial teams, which resulted in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/0001493152-23-024400-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"in the range of approximately $14.4 million to $14.6 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"a0d40fb9c2a3bda2fb578aea1b9a6643bf881ad2","claim":"Biofrontera Inc. reported the three months ended June 30, 2023 results: revenue in the range of approximately $5.7 million to $5.9 million. Guidance reaffirmed.","evidence_excerpt":"announced preliminary unaudited revenues for the three months ended June 30, 2023. Revenues for the second quarter of 2023 are anticipated to be in the range of approximately $5.7 million to $5.9 million, an increase of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/0001493152-23-024400-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Revenue","value":"in the range of approximately $5.7 million to $5.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}